Administration statements about acetaminophen and autism
Editorial record through October 30, 2026. Later developments are not reflected here.
What happened
Administration statements about taking acetaminophen during pregnancy and possible autism risk generated objections from doctors and researchers who said the publicly cited evidence did not establish a causal relationship.
What prompted public or expert concern
Observational studies may identify statistical associations, but factors such as underlying fever, pain, genetics and other health characteristics can complicate interpretation. Professional medical advice generally weighs the risks of untreated illness against potential treatment risks rather than relying on a single study.
Administration response and important qualifications
The controversy concerns how a government communicates preliminary scientific findings to pregnant patients and clinicians. Statements about association, causation, dosage and individual treatment decisions must be kept distinct.
Scientific evidence and federal communication
On September 22, 2025, the FDA initiated labeling changes suggesting a possible association between acetaminophen use during pregnancy and autism or ADHD. Trump administration statements about the issue brought heightened attention to an association that researchers had examined for years, but observational correlations do not on their own establish that a medication causes a developmental condition.
The American College of Obstetricians and Gynecologists said the weight of evidence did not support a causal link and maintained its clinical recommendations for appropriate acetaminophen use. Reviews accounting for familial and genetic differences have also questioned the association. Any patient decisions should distinguish the known risks of untreated fever or pain from uncertain observational findings.
What the FDA actually said
The FDA's September 22, 2025 notice to physicians acknowledged both studies reporting an association between prenatal acetaminophen exposure and neurodevelopmental conditions and studies reaching contrary findings. Crucially, the agency said a causal relationship had not been established. Its discussion of minimizing routine use also recognized acetaminophen as the safest over-the-counter fever-reducing and pain-relieving alternative during pregnancy among the medications it compared.
That qualification mattered because public statements implying that acetaminophen causes autism went beyond the evidence the FDA itself described. On the same date, the American College of Obstetricians and Gynecologists rejected the suggestion that acetaminophen use had been shown to cause autism and said its clinical recommendations remained in place. The controversy was not simply about evaluating potential risks; it was about whether federal messaging accurately conveyed the limits of observational research.